Why Regeneron Pharmaceuticals, Inc. (REGN) stock moved
Regeneron Pharmaceuticals, Inc. (REGN) shares fell 0.2% to $670.83 as of July 21, 2026, a slight decline from the prior close of $672.15. BestStocks flagged the session as a major change for REGN. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for REGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
REGN fell 0.2% to $670.83
REGN fell 0.2% in its latest session, moving from $672.15 to $670.83.
What it means for Regeneron Pharmaceuticals, Inc. investors
For Regeneron Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Regeneron Pharmaceuticals, Inc. (REGN) moved +2.18% from $664.45 to $678.94 on 2026-07-16, reaching a new 30-day high; Positive price momentum. Weighing against that: Negative session, down 0.2%; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $823.39, implying +22.7% upside from $670.83. Over the past 90 days analysts logged 1 upgrade and 2 downgrades. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 9 days out, the next report is the most likely near-term test of the move.
REGN price reaction
REGN last traded at $670.83, down $1.32 (-0.20%) from the previous close of $672.15. The session traded on 0.1× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $612.50 and $678.94, and it currently sits about 88% of the way up that band.
Bullish and bearish analyst opinions on Regeneron Pharmaceuticals, Inc. (REGN)
The consensus analyst price target on Regeneron Pharmaceuticals, Inc. (REGN) is $823.39, 22.7% above the recent $670.83. Over the past 90 days analysts logged 1 upgrade, 20 maintains, and 2 downgrades. Here is how the bullish and bearish cases on REGN line up.
The bullish case
- Wall Street's consensus price target of $823.39 implies +22.7% upside from $670.83.
- The Street's most bullish target is $1,000.00 (+49.1%).
- 1 analyst upgrade in the past 90 days, most recently Benchmark to Buy (2026-07-07).
- Regeneron Pharmaceuticals, Inc. (REGN) moved +2.18% from $664.45 to $678.94 on 2026-07-16, reaching a new 30-day high.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $641.00 (-4.4%).
- 2 analyst downgrades in the past 90 days, most recently Leerink Partners to Market Perform (2026-05-18).
- Negative session, down 0.2%.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for REGN
Frequently asked questions about REGN
Why did Regeneron Pharmaceuticals, Inc. (REGN) stock move?
REGN fell 0.2% to $670.83. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did REGN stock fall?
REGN lost 0.20% ($1.32) versus the prior close of $672.15, last trading at $670.83 on 0.1× average volume.
When is Regeneron Pharmaceuticals, Inc.'s next earnings date?
REGN's next earnings report is estimated for 2026-07-30 — about 9 days away.
What is the analyst price target for REGN?
The consensus analyst price target for REGN is $823.39, about 22.7% above the current $670.83. Over the past 90 days, analysts recorded 1 upgrade, 20 maintains, and 2 downgrades.
How BestStocks tracks REGN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared REGN-specific materiality thresholds, triggering an evidence check. It draws on 6 tracked change events for REGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.